Compare CVS Health Corp (CVS) vs Macy's Inc (M) Price & Performance

CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.

The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.

Macy's (M) trades at $22.79, up 1.47% today, with a bullish technical signal from moving averages. The stock shows attractive valuation with a P/E of 8.35 and P/S of 0.27. Recent earnings have consistently beaten estimates, and the company's 'Bold New Chapter' strategy is driving digital and omnichannel growth, though revenue has trended down from $25.3B in 2022 to $23.0B in 2025.

The outlook is mixed; strong cash flow and a 3.5% dividend yield support income investors, but competitive pressures and uneven growth pose risks. Analyst consensus is a $24.25 price target with a Hold bias. Execution of the turnaround strategy remains key to unlocking value amid retail sector challenges.